TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

A drug-resistant type of bacteria that has adapted to health care settings evolved in the past several years to weaponize an antimicrobial genetic tool, eliminating its cousins and replacing them as ...

A deadly hospital superbug has evolved into a global force by weaponizing a genetic tool to wipe out its microbial ...

A new study suggests that fluoxetine, commonly known as Prozac, may do more than treat depression. Researchers at the Salk ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...

Statistics show hundreds of thousands of systemic bacterial and fungal infections are diagnosed each year in the United ...

Rutgers researchers found that increased brown fat improves longevity and exercise capacity in mice. They aim to develop a ...

Chronic metabolic diseases with increasing prevalence and morbidity have posed serious challenges to the global healthcare ...

When Bridger Lee Jensen opened a spiritual center in Provo, Utah, he contacted city officials to let them know what would be ...

AWS and Cisco partner PTP acquires two MSPs in Stratogent and Protocol Networks to boost cloud services and AI for life ...

Historically, new drug development has relied heavily on broader and more empirical approaches ... In cancer research, for instance, the discovery of specific oncogenes such as breast cancer ...

With the new AI tool, experts found that the antidepressant Lexapro may help prevent heart failure, a leading cause of death ...